Clinical Trial

Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels

Study acronym: ATTACH
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Multicenter, Open-label, Single arm Trial with Matched Historical controls. Male and female adults with compensated liver cirrhosis due to chronic hepatitis B virus infection who have low-level viremia. To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events (hepatocellular carcinoma, liver-related events and death, decompensated liver cirrhosis) in cirrhotic chronic hepatitis B patients with low-level viremia compared with matched historical controls.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-03-01; most recent amendment 2024-10-07.
Status change: Recruiting → Active, Not Recruiting 2024-10-07
Status change: Not Yet Recruiting → Recruiting 2021-09-13
Trial Details
NCT Number NCT04780204
Lead Sponsor Asan Medical Center
Collaborators: National Evidence-Based Healthcare Collaborating Agency
Conditions Hepatitis B, Chronic
Enrollment 600 participants
Start Date 2021-08-23
Primary Completion 2027-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-09